Over 200 companies advancing 220+ glioblastoma drugs in clinical trials, signaling progress in brain cancer treatment.
More than 200 companies are actively developing over 220 drugs for glioblastoma, the most aggressive brain cancer, with 16+ drugs in late-stage trials. Key therapies include targeted treatments, immunotherapies, and metabolic modulators, reflecting a...
